A fundamental analysis of Alembic Pharma (APLLTD) covering revenue trends, profitability, valuation, and shareholding patterns.
Alembic Pharma Revenue Trend
Revenue rose 7.3% to ₹6,715 Cr in FY2025 for Alembic Pharma, against ₹6,257 Cr the year before.
Stepping back, the 10-year revenue CAGR of 12.6% tells a positive story. Alembic Pharma has been growing at a solid clip.
In terms of scale, Alembic Pharma's ₹6,715 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
Alembic Pharma has posted revenue growth for 3 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹6,715 Cr | +7.3% |
| FY2024 | ₹6,257 Cr | +10.6% |
| FY2023 | ₹5,655 Cr | +5.6% |
| FY2022 | ₹5,356 Cr | -0.9% |
| FY2021 | ₹5,403 Cr | — |
View Alembic Pharma's full 10-year revenue trend with CAGR analysis →
Alembic Pharma Profitability
On the earnings front, Alembic Pharma posted ₹582 Cr for FY2025 — a 5.5% drop from ₹616 Cr in FY2024.
Margins came under pressure in FY2025, with net profit margin dropping to 8.7% from 9.8%.
The diluted EPS figure moved down to ₹29.68 in FY2025, against ₹31.33 posted in FY2024.
Is Alembic Pharma Undervalued
The P/E Ratio approach puts Alembic Pharma's intrinsic value at ₹851, a 17.6% upside from the current market price.
Alembic Pharma shares are currently trading at ₹723.55.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹851 | 17.6% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Alembic Pharma with detailed assumptions →
Alembic Pharma Shareholding Pattern
Promoters haven't moved — their 69.7% holding has been unchanged for 4 quarters.
Foreign institutions moved their stake up to 4.2% from 4.0% over the past year.
On the domestic institutional side, the holding is 16.2% as of March 2026 — down from 16.5%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 69.7% | 4.2% | 16.2% | 9.8% |
| Dec 2025 | 69.7% | 4.2% | 16.2% | 9.8% |
| Sep 2025 | 69.7% | 4.0% | 16.3% | 9.9% |
| Jun 2025 | 69.7% | 4.0% | 16.5% | 9.9% |
Track quarterly shareholding changes for Alembic Pharma →
Alembic Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹77.73B, up 20.6% YoY from ₹64.46B.
Property, Plant & Equipment accounts for 43.2% of the total, ahead of Inventories (29.4%) and Receivables (18.0%).
Capital structure: 66.8% equity, 16.2% debt, 17.1% operating liabilities. Over the year, debt is up 145.1% and equity is up 7.7%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 834.80M |
| Receivables | 14.00B |
| Inventories | 22.88B |
| Property, Plant & Equipment | 33.61B |
| Investments | 1.27B |
| Other Assets | 5.14B |
| Category | Value |
|---|---|
| Equity | 51.90B |
| Short-term Debt | 12.11B |
| Long-term Debt | 467.70M |
| Trade Payables | 8.80B |
| Other Liabilities | 4.46B |
What Stands Out About Alembic Pharma
What should investors take away from Alembic Pharma's (APLLTD) latest numbers? Here's the summary.
Revenue of ₹6,715 Cr in FY2025, up 7.3% year-over-year.
Long-term revenue has been compounding at 12.6% annually over 10 years.
The company is profitable, with a net margin of 8.7% and net income of ₹582 Cr.
The P/E Ratio model implies 17.6% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Craytheon's full analysis of Alembic Pharma goes deeper: three valuation models, growth metrics, and 10 years of financial data.